Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HOTH | Hoth Therapeutics, Inc.

Index- P/E- EPS (ttm)-6.18 Insider Own2.90% Shs Outstand3.30M Perf Week-14.67%
Market Cap4.95M Forward P/E- EPS next Y-1.45 Insider Trans0.00% Shs Float3.26M Perf Month-34.58%
Income-10.20M PEG- EPS next Q-0.72 Inst Own8.30% Short Float / Ratio3.52% / 0.50 Perf Quarter-49.19%
Sales- P/S- EPS this Y40.70% Inst Trans0.77% Short Interest0.11M Perf Half Y-19.90%
Book/sh3.01 P/B0.52 EPS next Y48.90% ROA-96.90% Target Price5.25 Perf Year-83.14%
Cash/sh3.65 P/C0.43 EPS next 5Y- ROE-114.50% 52W Range1.52 - 12.50 Perf YTD-79.87%
Dividend- P/FCF- EPS past 5Y-12.20% ROI- 52W High-87.44% Beta0.51
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low3.29% ATR0.25
Employees2 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)31.53 Volatility8.95% 12.71%
OptionableNo Debt/Eq0.00 EPS Q/Q73.70% Profit Margin- Rel Volume0.68 Prev Close1.66
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume230.93K Price1.57
Recom2.00 SMA20-25.98% SMA50-33.95% SMA200-46.35% Volume156,622 Change-5.42%
Date Action Analyst Rating Change Price Target Change
Oct-15-19Initiated The Benchmark Company Speculative Buy $10
Sep-15-23 02:38PM
Sep-13-23 01:43PM
Sep-11-23 10:04AM
Sep-06-23 08:12AM
08:13AM Loading…
Aug-09-23 08:13AM
Jul-25-23 08:12AM
Jul-19-23 08:02AM
Jun-14-23 08:12AM
Jun-06-23 03:01PM
May-12-23 08:38AM
Apr-26-23 04:21PM
Mar-08-23 09:09AM
08:35AM Loading…
Feb-16-23 08:35AM
Feb-08-23 10:42AM
Jan-25-23 08:27AM
Jan-03-23 04:38PM
Dec-29-22 08:00PM
Dec-01-22 10:45AM
Nov-09-22 12:38PM
Oct-31-22 11:39AM
Oct-24-22 04:15PM
Sep-20-22 09:05AM
Sep-06-22 08:21AM
03:00PM Loading…
Aug-16-22 03:00PM
Aug-12-22 01:48PM
Jul-12-22 02:24PM
Jun-29-22 01:25PM
Jun-21-22 12:30PM
Jun-15-22 12:30PM
Jun-09-22 08:18AM
May-06-22 09:02AM
May-03-22 08:09AM
Apr-19-22 03:29PM
Apr-14-22 01:02PM
Apr-12-22 08:17AM
Apr-11-22 11:31PM
Apr-01-22 08:02AM
Mar-22-22 09:48AM
Mar-11-22 08:00AM
Feb-09-22 10:10AM
Feb-07-22 08:02AM
Jan-31-22 08:17AM
Jan-05-22 05:18AM
Jan-04-22 02:13PM
Dec-21-21 07:59AM
Dec-08-21 08:00AM
Nov-30-21 08:00AM
Nov-16-21 08:30AM
Nov-08-21 08:38AM
Oct-19-21 12:47PM
Oct-12-21 10:04AM
Sep-22-21 07:00AM
Sep-21-21 10:05AM
Sep-08-21 08:02AM
Aug-11-21 09:01AM
Aug-02-21 08:15AM
Jul-13-21 10:13AM
Jun-28-21 08:01AM
Jun-13-21 11:23PM
Jun-10-21 04:16AM
Jun-07-21 02:31PM
Jun-03-21 12:32PM
Jun-01-21 08:05AM
May-24-21 08:01AM
May-13-21 08:28AM
May-05-21 09:24AM
May-03-21 09:13AM
Apr-22-21 09:01AM
Apr-20-21 09:06AM
Apr-13-21 08:00AM
Apr-12-21 09:15AM
Apr-06-21 09:15AM
Apr-05-21 08:01AM
Mar-24-21 10:26AM
Mar-23-21 08:01AM
Mar-22-21 08:00AM
Mar-19-21 07:00AM
Mar-17-21 02:20PM
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylo Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.